Home / Conferences


11th EGA Legal Affairs Forum

11th EGA Legal Affairs Forum
26−27 March 2015
Thon Hotel EU, Brussels, Belgium

EBG Biosimilars 2015 / 13th EGA-European Biosimilars Group Conference

EBG Biosimilars 2015
13th EGA-European Biosimilars Group Conference
23−24 April 2015
Grange Tower Bridge Hotel, London, UK

Biosimilars 2015

Informa Life Sciences’ Annual Biosimilars 2015
Date: 18−20 May 2015
Venue: Maritim proArte Hotel Berlin, Berlin, Germany

World Biosimilar Congress USA 2015

World Biosimilar Congress USA 2015
Date: 27–28 May 2015
Venue: Marriott San Diego Mission Valley, San Diego, CA, USA

French generics association promotes biosimilars

French generics association GEMME held its first symposium on the challenges and opportunities associated with biosimilars in France on 3 October 2014.

Topics presented at the 16th IGPA conference on generics

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.

EGA pushes for increased focus on generics and biosimilars

EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.

Report on 25th Annual EuroMeeting, 4-6 March 2013, Amsterdam, The Netherlands

Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, addressed by 300+ Speakers from EMA, European Commission, FDA and other national regulatory agencies. Most popular sessions included Implementation of the New Pharmacovigilance Legislation, the Regulatory Town Hall Meeting and the sell-out European Landscape on HTA - the EUnetHTA Joint Action. Eighteen pre-conference tutorials were led by an expert faculty and 120 students, young professional and patients all attended sessions created especially for them.

Patient power predominates at DIA Europe’s Clinical Forum

DIA Europe’s 2012 Clinical Forum in October this year promises to be an important multidisciplinary conference for all engaged in the clinical development and therapeutic use of medicines. The theme for 2012 is ‘The Empowered Patient’, an acknowledgement of the inescapable fact that the evolution of technology and electronic communication has given patients the ability to find and share health information which will impact their treatment choices – empowering them to become more engaged in their care and to participate in decisions about it.

Need for global development programme for biosimilars

There is now a crucial need for a framework that allows global biosimilars development.

Generics News Research General


Biosimilars News Research General